News
-
-
-
PRESS RELEASE
VALBIOTIS SA: Valbiotis announces completion of recruitment for the Cardio-Liver clinical study conducted with TOTUM•448 for metabolic liver diseases (MASLD)
Valbiotis announces completion of recruitment for the Cardio-Liver clinical study with TOTUM•448 for metabolic liver diseases. Results expected in 2026 -
-
-
PRESS RELEASE
Correction of a release from 17.11.2025 17:40 CET/CEST - VALBIOTIS SA: Valbiotis announces a major strategic agreement in Asia
Valbiotis announces strategic agreement with Chinese group Aika to commercialize ValbiotisPRO® products in multiple Asian markets starting in 2026, leveraging CBEC model for rapid market entry -
-
-
-